Conditions: Asthma
Keywords: asthma allergic asthma QGE031 open-label IgE long-term safety
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 270
Healthy volunteers: no

Brief summary:
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.

Detailed description:
This study planned to assess long-term safety and tolerability of QGE031 administered every 4 weeks for an additional 12 months in patients with allergic asthma who previously completed study CQGE031B2201. The study was terminated early due to the efficacy results from an interim analysis of the Phase II study CQGE031B2201.

Arms:
arm 1: QGE031 240 mg subcutaneously q4w

Interventions: intervention 1: QGE031
Intervention descriptions: intervention 1: QGE031 120 mg/mL solution for subcutaneous injection

Protocol document: